Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7M66

Targeting Enterococcus faecalis HMG-CoA reductase with a novel non-statin inhibitor

Summary for 7M66
Entry DOI10.2210/pdb7m66/pdb
Related7M1Z 7M3H
DescriptorHydroxymethylglutaryl-CoA reductase, degradative, SULFATE ION, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, ... (7 entities in total)
Functional Keywordsantibiotic, bacterial, hmg-coa reductase, antimicrobial protein
Biological sourceEnterococcus faecalis (Streptococcus faecalis)
Total number of polymer chains4
Total formula weight186876.32
Authors
Bose, S.,Steussy, C.N. (deposition date: 2021-03-25, release date: 2022-09-28, Last modification date: 2024-05-22)
Primary citationBose, S.,Steussy, C.N.,Lopez-Perez, D.,Schmidt, T.,Kulathunga, S.C.,Seleem, M.N.,Lipton, M.,Mesecar, A.D.,Rodwell, V.W.,Stauffacher, C.V.
Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor.
Commun Biol, 6:360-360, 2023
Cited by
PubMed Abstract: HMG-CoA reductase (HMGR), a rate-limiting enzyme of the mevalonate pathway in Gram-positive pathogenic bacteria, is an attractive target for development of novel antibiotics. In this study, we report the crystal structures of HMGR from Enterococcus faecalis (efHMGR) in the apo and liganded forms, highlighting several unique features of this enzyme. Statins, which inhibit the human enzyme with nanomolar affinity, perform poorly against the bacterial HMGR homologs. We also report a potent competitive inhibitor (Chembridge2 ID 7828315 or compound 315) of the efHMGR enzyme identified by a high-throughput, in-vitro screening. The X-ray crystal structure of efHMGR in complex with 315 was determined to 1.27 Å resolution revealing that the inhibitor occupies the mevalonate-binding site and interacts with several key active site residues conserved among bacterial homologs. Importantly, 315 does not inhibit the human HMGR. Our identification of a selective, non-statin inhibitor of bacterial HMG-CoA reductases will be instrumental in lead optimization and development of novel antibacterial drug candidates.
PubMed: 37012403
DOI: 10.1038/s42003-023-04639-y
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.25 Å)
Structure validation

250835

PDB entries from 2026-03-18

PDB statisticsPDBj update infoContact PDBjnumon